Measurable disease confirmed by central lab at Screening, defined by at least  of the following:
Measurable disease defined by laboratory test results
Measurable disease defined as any of the following:
Measurable, secretory disease as defined by any of the following:
Subjects must have measurable disease defined as at least  of the following:
Patients must have measurable disease defined by at least  of the following  measurements:
Measurable disease defined as any of the following:
Disease status as defined as.
Measurable disease at Screening as defined by any of the following:
Must have measurable disease defined by:
Must have measurable disease defined by at least  of the following  measurements:
Confirmed measurable MM based on the following:
Have measurable disease by at least  of the following measurements:
Criteria  Measurable disease with at least  of the following assessed within  days prior to randomization:
Patient with measurable progressive disease defined by at least one of the following two measurements:
Measurable disease at screening as defined per protocol.
Measurable disease defined by  or more of the following:
Measurable disease of MM as defined by at least ONE of the following:
Patients with measurable disease defined as at least one of the following:
Measurable disease defined by at least ONE of the following:
Patient has measurable disease defined as any of the following:
Measurable disease defined as one or both of the following
Measurable disease with at least  of the following assessed within the  days prior to randomization:
Measurable disease as indicated by  or more of the following:
Must have had measurable disease, defined by at least  of the following  measurements:
During the dose expansion part of the study patients must have measurable disease defined by at least  of the following  measurements:
Must have measurable disease defined as:
Patients with measurable disease defined as at least one of the following
Measurable disease assessed by one of the following ? days prior to registration:
For patients in the Phase II portion of the study, must have measurable disease defined by at least  of the following  measurements:
Measurable disease, as defined by  or more of the following (assessed within  days prior to randomization):
Measurable disease, as indicated by one or more of the following:
Measurable disease defined as at least one of the following:
Measurable disease defined as at least one of the following:
Measurable disease defined as at least one of the following:
Measurable disease, as defined by one or more of the following (assessed within  days prior to randomization):
Symptomatic, histologically confirmed MM, based on IMWG guidelines. Patients must have measurable disease as defined by at least one of the following:
Measurable disease, including at least one of the following:
Histologically confirmed MM with measurable disease per IMWG guidelines as defined by at least  of the following:
For Participants with MM, measurable disease defined as one of the following: